234 related articles for article (PubMed ID: 15988427)
1. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke.
Brown DL; Barsan WG; Lisabeth LD; Gallery ME; Morgenstern LB
Ann Emerg Med; 2005 Jul; 46(1):56-60. PubMed ID: 15988427
[TBL] [Abstract][Full Text] [Related]
2. Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?
Lee SH; Kim BJ; Han MK; Park TH; Lee KB; Lee BC; Yu KH; Oh MS; Cha JK; Kim DH; Nah HW; Lee J; Lee SJ; Ko Y; Kim JG; Park JM; Kang K; Cho YJ; Hong KS; Choi JC; Kim JT; Choi K; Kim DE; Ryu WS; Kim WJ; Shin DI; Yeo M; Lee J; Lee JS; Gorelick PB; Bae HJ
Int J Stroke; 2016 Oct; 11(7):783-90. PubMed ID: 27312681
[TBL] [Abstract][Full Text] [Related]
3. Ginsenoside Represses Symptomatic Intracerebral Hemorrhage after Recombinant Tissue Plasminogen Activator Therapy by Promoting Transforming Growth Factor-β1.
Chen J; Bai Q; Zhao Z; Sui H; Xie X
J Stroke Cerebrovasc Dis; 2016 Mar; 25(3):549-55. PubMed ID: 26683593
[TBL] [Abstract][Full Text] [Related]
4. The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
Flint AC; Gupta R; Smith WS; Kamel H; Faigeles BS; Cullen SP; Rao VA; Bath PM; Wahlgren N; Ahmed N; Donnan GA;
Int J Stroke; 2014 Aug; 9(6):705-10. PubMed ID: 25042855
[TBL] [Abstract][Full Text] [Related]
5. Hesperidin reduces adverse symptomatic intracerebral hemorrhage by promoting TGF-β1 for treating ischemic stroke using tissue plasminogen activator.
Qin Z; Chen L; Liu M; Tan H; Zheng L
Neurol Sci; 2020 Jan; 41(1):139-147. PubMed ID: 31478148
[TBL] [Abstract][Full Text] [Related]
6. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group
Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134
[TBL] [Abstract][Full Text] [Related]
7. Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke.
Al-Khaled M; Matthis C; Eggers J
J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):7-11. PubMed ID: 22578915
[TBL] [Abstract][Full Text] [Related]
8. Utilization of intravenous thrombolysis in 3-4.5 hours: analysis of the Minnesota stroke registry.
Tekle WG; Chaudhry SA; Hassan AE; Peacock JM; Lakshminarayan K; Tsai A; Luepker R; Anderson DC; Qureshi AI
Cerebrovasc Dis; 2012; 34(5-6):400-5. PubMed ID: 23221276
[TBL] [Abstract][Full Text] [Related]
9. Frequency and predictors of symptomatic intracerebral hemorrhage in patients with ischemic stroke treated with recombinant tissue plasminogen activator outside clinical trials.
Martí-Fàbregas J; Bravo Y; Cocho D; Martí-Vilalta JL; Díaz-Manera J; San Román L; Puig M; Blanco M; Castellanos M; Millán M; Roquer J; Obach V; Maestre J
Cerebrovasc Dis; 2007; 23(2-3):85-90. PubMed ID: 17114877
[TBL] [Abstract][Full Text] [Related]
10. Is there a decreased risk of intracerebral hemorrhage and mortality in obese patients treated with intravenous thrombolysis in acute ischemic stroke?
Hassan AE; Chaudhry SA; Jani V; Grigoryan M; Khan AA; Adil MM; Qureshi AI
J Stroke Cerebrovasc Dis; 2013 May; 22(4):545-9. PubMed ID: 23453555
[TBL] [Abstract][Full Text] [Related]
11. Enablers of the implementation of tissue plasminogen activator in acute stroke care: a cross-sectional survey.
Grady A; Bryant J; Carey M; Paul C; Sanson-Fisher R
PLoS One; 2014; 9(12):e114778. PubMed ID: 25490546
[TBL] [Abstract][Full Text] [Related]
12. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
[TBL] [Abstract][Full Text] [Related]
13. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.
Stroke; 1997 Nov; 28(11):2109-18. PubMed ID: 9368550
[TBL] [Abstract][Full Text] [Related]
14. Attitudes and beliefs of Michigan emergency physicians toward tissue plasminogen activator use in stroke: baseline survey results from the INcreasing Stroke Treatment through INteractive behavioral Change Tactic (INSTINCT) trial hospitals.
Scott PA; Xu Z; Meurer WJ; Frederiksen SM; Haan MN; Westfall MW; Kothari SU; Morgenstern LB; Kalbfleisch JD
Stroke; 2010 Sep; 41(9):2026-32. PubMed ID: 20705931
[TBL] [Abstract][Full Text] [Related]
15. Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis: Predictive Factors and Validation of Prediction Models.
Nisar T; Hanumanthu R; Khandelwal P
J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104360. PubMed ID: 31501036
[TBL] [Abstract][Full Text] [Related]
16. Agreement with evidence for tissue Plasminogen Activator use among emergency physicians: a cross-sectional survey.
Grady AM; Bryant J; Carey ML; Paul CL; Sanson-Fisher RW; Levi CR
BMC Res Notes; 2015 Jun; 8():267. PubMed ID: 26111807
[TBL] [Abstract][Full Text] [Related]
17. Hematoma expansion in experimental intracerebral hemorrhage is not altered by peracute treatment with recombinant tissue plasminogen activator.
Pfeilschifter W; Kashefiolasl S; Lauer A; Steinmetz H; Foerch C
Neuroscience; 2013 Oct; 250():181-8. PubMed ID: 23856067
[TBL] [Abstract][Full Text] [Related]
18. Emergency physician treatment of acute stroke with recombinant tissue plasminogen activator: a retrospective analysis.
Smith RW; Scott PA; Grant RJ; Chudnofsky CR; Frederiksen SM
Acad Emerg Med; 1999 Jun; 6(6):618-25. PubMed ID: 10386679
[TBL] [Abstract][Full Text] [Related]
19. Wake-up stroke within 3 hours of symptom awareness: imaging and clinical features compared to standard recombinant tissue plasminogen activator treated stroke.
Roveri L; La Gioia S; Ghidinelli C; Anzalone N; De Filippis C; Comi G
J Stroke Cerebrovasc Dis; 2013 Aug; 22(6):703-8. PubMed ID: 22133742
[TBL] [Abstract][Full Text] [Related]
20. Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis.
Balucani C; Levine SR; Khoury JC; Khatri P; Saver JL; Broderick JP
J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):894-901. PubMed ID: 26825352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
